In the clinic, the radiation dose set to kill cancer cells in patients is limited with respect to normal tissue tolerance, thus our findings suggest PFKFB3 inhibition as an attractive approach to potentially achieve cancer-specific DNA repair deficiency upon radiation therapy. Here, PFKFB3 is linked to cancer.